Development Level

Tbio 21 | 10,625
Tchem 3 | 1,890
Tclin 1 | 602

IMPC Term

decreased leukocyte cell numbe... 2 | 54
preweaning lethality, complete... 2 | 633
abnormal behavior 1 | 226
abnormal bone structure 1 | 131
abnormal coat appearance 1 | 25
abnormal coping response 1 | 12
abnormal embryo size 1 | 112
abnormal forebrain development 1 | 18
abnormal hindbrain development 1 | 24
abnormal midbrain development 1 | 22
abnormal neural tube closure 1 | 37
abnormal pericardium morpholog... 1 | 11
abnormal posture 1 | 5
cardiovascular system phenotyp... 1 | 35
decreased body length 1 | 108
decreased bone mineral content 1 | 157
decreased bone mineral density 1 | 126
decreased caudal vertebrae num... 1 | 49
decreased grip strength 1 | 123
decreased lean body mass 1 | 195
decreased mean corpuscular hem... 1 | 34
decreased total body fat amoun... 1 | 186
decreased vertical activity 1 | 22
embryonic lethality prior to t... 1 | 187
hypoactivity 1 | 89
increased circulating HDL chol... 1 | 63
increased circulating LDL chol... 1 | 15
increased circulating calcium ... 1 | 32
preweaning lethality, incomple... 1 | 260
short tibia 1 | 82

Disease

glioblastoma 17 | 5,572
ovarian cancer 17 | 8,492
medulloblastoma, large-cell 15 | 6,234
osteosarcoma 14 | 7,933
Cancer 11 | 2,346
psoriasis 11 | 6,685
oligodendroglioma 10 | 2,849
atypical teratoid / rhabdoid tumor 9 | 4,369
lung cancer 9 | 4,473
Pick disease 8 | 1,893
pediatric high grade glioma 8 | 2,712
pilocytic astrocytoma 8 | 3,086
primitive neuroectodermal tumor 8 | 3,031
malignant mesothelioma 7 | 3,163
subependymal giant cell astrocytoma 7 | 2,287
astrocytoma 6 | 1,493
interstitial cystitis 6 | 2,299
pituitary cancer 6 | 1,972
Carcinoma 5 | 2,147
adult high grade glioma 5 | 2,148
astrocytic glioma 5 | 2,241
invasive ductal carcinoma 5 | 2,950
medulloblastoma 5 | 1,524
non-small cell lung cancer 5 | 2,798
Rheumatoid Arthritis 4 | 1,171
acute quadriplegic myopathy 4 | 1,157
adrenocortical carcinoma 4 | 1,427
breast carcinoma 4 | 1,614
ependymoma 4 | 2,514
intraductal papillary-mucinous carcinoma (IPMC) 4 | 2,988
intraductal papillary-mucinous neoplasm (IPMN) 4 | 3,289
pancreatic cancer 4 | 2,300
primary pancreatic ductal adenocarcinoma 4 | 1,271
Breast cancer 3 | 3,099
Multiple Sclerosis 3 | 498
Multiple myeloma 3 | 1,328
Prostatic Neoplasms 3 | 471
acute myeloid leukemia 3 | 785
chronic lymphocytic leukemia 3 | 244
group 4 medulloblastoma 3 | 1,875
hepatocellular carcinoma 3 | 550
intraductal papillary-mucinous adenoma (IPMA) 3 | 2,956
juvenile dermatomyositis 3 | 1,189
lung carcinoma 3 | 2,844
pancreatic ductal adenocarcinoma liver metastasis 3 | 1,795
posterior fossa group A ependymoma 3 | 1,511
primary Sjogren syndrome 3 | 789
progressive supranuclear palsy 3 | 674
spina bifida 3 | 1,064
tuberculosis 3 | 1,563
ulcerative colitis 3 | 2,087
Adenocarcinoma 2 | 115
Animal Mammary Neoplasms 2 | 136
Cholangiocarcinoma 2 | 32
Cleft palate 2 | 125
Colonic Neoplasms 2 | 126
Craniofacial Abnormalities 2 | 147
Disease Progression 2 | 125
Endometriosis 2 | 535
Intellectual disability 2 | 573
Liver carcinoma 2 | 217
Lung Neoplasms 2 | 171
Mammary Neoplasms 2 | 410
Mammary Neoplasms, Experimental 2 | 150
Myofibrillar myopathy 1 2 | 6
Myofibrillar myopathy 3 2 | 5
Neoplasm Invasiveness 2 | 127
Neoplasm Metastasis 2 | 138
Pick's disease 2 | 14
Spinocerebellar ataxia type 2 2 | 19
aldosterone-producing adenoma 2 | 664
atypical teratoid/rhabdoid tumor 2 | 1,095
dermatomyositis 2 | 967
ductal carcinoma in situ 2 | 1,745
esophageal adenocarcinoma 2 | 737
fibroadenoma 2 | 557
gastric cancer 2 | 436
gastric carcinoma 2 | 832
group 3 medulloblastoma 2 | 2,254
lung adenocarcinoma 2 | 2,714
non primary Sjogren syndrome sicca 2 | 840
Angelman syndrome 1 | 38
Barrett's esophagus 1 | 185
Carcinoma of colon 1 | 32
DOID:2627 1 | 14
Enamel caries 1 | 8
Esophageal Neoplasms 1 | 67
Familial adenomatous polyposis 1 | 33
Glioma 1 | 66
Leukemia, Acute Myeloid 1 | 17
Leukemia, Myelocytic, Acute 1 | 113
Lung diseases 1 | 48
Melanoma 1 | 261
Nasopharyngeal Neoplasms 1 | 8
Neoplasm Recurrence, Local 1 | 23
Squamous cell carcinoma 1 | 96
Squamous cell carcinoma of esophagus 1 | 82
Tetralogy of Fallot 1 | 38
non-inflammatory breast cancer 1 | 208
ovarian neoplasm 1 | 97

Tissue

Blood and immune system 25 | 17,995
Cardiovascular System 25 | 17,958
Digestive Tract 25 | 18,473
Endocrine System 25 | 18,512
Female tissues 25 | 18,647
Liver and Pancreas 25 | 18,136
Male tissues 25 | 17,969
Nervous System 25 | 18,561
Respiratory system 25 | 17,484
Skin and soft tissues 25 | 18,115
Urinary Tract 25 | 18,444

Target Family

Non-IDG 17 | 11,969
Enzyme 7 | 4,146
Kinase 1 | 634

Reactome Pathway

EGFR downregulation 25 | 25
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
Infectious disease 392 | 392
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Protein sprouty homolog 1 SPRY1 Tbio Non-IDG -2.16395 131.0 148
Protein sprouty homolog 2 SPRY2 Tbio Non-IDG -1.86730 81.5 178
Polyubiquitin-C UBC Tbio Non-IDG -2.87696 56.7 130
Polyubiquitin-B UBB Tbio Non-IDG -1.96206 92.3 370
Tyrosine-protein phosphatase non-receptor type 3 PTPN3 Tbio Enzyme -1.39351 28.5 147
Epsin-1 EPN1 Tbio Non-IDG -1.49983 30.4 133
Endophilin-A2 SH3GL1 Tbio Non-IDG -2.08498 115.6 229
Endophilin-A1 SH3GL2 Tbio Non-IDG -1.76003 55.9 226
Endophilin-A3 SH3GL3 Tbio Non-IDG -1.03659 9.86 73
Epidermal growth factor receptor substrate 15 EPS15 Tbio Non-IDG -2.27598 171.7 162